2019 Fiscal Year Final Research Report
Development of SEREX-Ag targeting antibody panel for gastric cancer
| Project/Area Number |
15K10117
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Toho University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
島田 英昭 東邦大学, 医学部, 教授 (20292691)
根本 哲生 東邦大学, 医学部, 准教授 (70242203)
名波 竜規 東邦大学, 医学部, 助教 (90385831)
|
|---|
| Project Period (FY) |
2015-04-01 – 2020-03-31
|
| Keywords | 胃癌 / 腫瘍マーカー / 抗体型腫瘍マーカー / ELISA / SEREX / HSP70 / KM-HN-1 / NY-ESO-1 |
|---|
| Outline of Final Research Achievements |
Although HSP70 antibody showed similar positive rate as p53 antibody, KM-HN-1 antibody was only a half the positive rate of p53 antibody. Immunohistochemical staining for HSP70 showed a correlation with clinicopathological factors, and there was no statistically significant difference.The prognosis of the patients tended to be poor in immunostaining positive cases. With respect to KM-HN-1, the immunohistochemical characteristics are less clear. According to a recent report, an immune checkpoint inhibitor has a high therapeutic effect in autoantibody-positive cases.
|
| Free Research Field |
消化器外科学
|
| Academic Significance and Societal Importance of the Research Achievements |
複数の抗体を併用する方法を開発した。我々が実用化したこれらの自己抗体解析ELISAキットを用いて、免疫チェックポイント阻害剤による治療を行った症例の治療効果や予後を解析することで、これらの自己抗体の意義を明らかとする予定である。
|
